Two valued members of the Foundation's family have been elected to the Board of Directors for the International Society for Therapeutic Ultrasound (ISTU).
The Core Hub for Medical Research of UltraSound (CHORUS) is a focused ultrasound research facility located within the Department of Radiology at Seoul National University Hospital in Korea. The group’s incredibly wide breadth of applications combined with their multifaceted internal and external collaborations has created a highly productive environment for clinical and preclinical research. Importantly, CHORUS scientists recently discovered a potential mechanism for how focused ultrasound treatment clears amyloid plaques in Alzheimer’s disease. We interviewed Jae Young Lee, MD, PhD, to learn more about one of Seoul’s many impressive focused ultrasound centers.
Liquid biopsies are emerging as a method to analyze the molecular profile of tumors through a simple blood test. Solid tumors shed biomarkers that circulate throughout the body in the bloodstream. The most common primary malignant brain tumors in adults – glioblastomas – represent a unique problem as conventional biopsies may not reflect the tumor heterogeneity that makes these tumors highly resistant to many treatments. In addition, repeated biopsies to monitor changes in tumor genetics over time are not feasible in the brain. Therefore, liquid biopsies may represent a noninvasive way to better define the heterogeneity of glioblastomas, monitor response and resistance to treatment, and direct targeted therapies.
Stephen Bagley, MD, MSCE, Assistant Professor of Medicine at the University of Pennsylvania, recently presented a webinar where he gave an overview of the current state of research for liquid biopsy in patients with brain tumors and introduced the technique's potential to help assess the tumor immune environment and guide patient selection for immunotherapies. He also presented the emerging data on using focused ultrasound to enhance the yield of liquid biopsies for brain tumors.
Liquid Biopsy for Brain Tumors: Recent Advances and Future Directions
Stephen J. Bagley, MD, MSCE
Assistant Professor of Medicine
University of Pennsylvania Perelman School of Medicine
Abramson Cancer Center and Penn Brain Tumor Center
WATCH NOW >
About the Speaker
Dr. Bagley is an Assistant Professor in the Division of Hematology/Oncology at the University of Pennsylvania Perelman School of Medicine and a board-certified medical oncologist. His primary area of research and clinical interest is in Neuro-Oncology. After completing medical school, residency, and fellowship at Penn, Dr. Bagley completed a formal clinical research training program to obtain a Master of Science in Clinical Epidemiology degree, with a formal concentration in the design and analysis of clinical trials. His current clinical and translational research focus is the development of early phase, investigator-initiated clinical trials for glioblastoma, as well as novel methods for integrating liquid biopsy into the care of patients with brain tumors. He is the principal investigator of multiple currently enrolling brain tumor trials at Penn and leads Penn’s research efforts to develop liquid biopsy patients with glioblastoma.
On Wednesday, June 24, the Foundation hosted a special conversation with Jill O’Donnell-Tormey, PhD, CEO of the Cancer Research Institute (CRI) and the Foundation's Chief Scientific Officer, Jessica Foley, PhD.
The Cancer Research Institute is a leader in the field of cancer immunotherapy and important partner to the Foundation. Drs. O'Donnell-Tormey and Foley discussed the lifesaving potential of cancer immunotherapy and the ways that CRI and the Foundation are working together to advance exciting research, through a lens of the new COVID-19 environment.
Cancer Immunotherapy Treatment and Research in a COVID-19 World
Jill O'Donnell-Tormey, PhD
Chief Executive Officer and Director of Scientific Affairs, Cancer Research Institute
Jessica Foley, PhD
Chief Scientific Officer, Focused Ultrasound Foundation
Wednesday, June 24, 2020
Jill O’Donnell-Tormey, PhD
Jill O’Donnell-Tormey, PhD, is chief executive officer and director of scientific affairs of the Cancer Research Institute (CRI), a nonprofit organization founded in 1953 that is today the global leader in supporting and coordinating research aimed at harnessing the immune system’s power to conquer all cancers. She joined the organization in 1987, and has been chief executive since 1993. Prior to joining CRI, she served as a research associate in the department of medicine at Cornell University Medical College and as a postdoctoral fellow in the laboratory of cellular physiology and immunology at The Rockefeller University.
Jessica Foley, PhD
Jessica Foley, PhD joined the Foundation in 2012 after a more than 11-year career in the field of focused ultrasound that spanned academic, industrial and government worlds. As Chief Scientific Officer, Foley guides the strategy, development, and implementation of the scientific and research programs and activities within the Foundation, and aligns these with communications and development efforts. She also leads alliance-building efforts with external stakeholders including (but not limited to) governmental policymakers, regulatory agencies, and disease-specific foundations whose interests are complementary to those of the Foundation. She is a representative and advocate for the Foundation and the focused ultrasound community among a wide variety of stakeholders. Her experience prior to the Foundation included several years with InSightec as the Neuro Projects Manager and Clinical Marketing Manager; Senior Scientist at Medtronic; and serving as a 2011-2012 AAAS Science and Technology.